多替阿巴拉米片需要吃几天
On January 22, 2018, GlaxoSmithKline (GSK) announced that its new drug for the treatment of HIV (Simeikat) was officially launched in mainland China. Dolutea abalamide tablets (Sumeikat) is a single-piece compound preparation with the new generation integrase inhibitor dolutegravir (DTG) as the core. It is also the first single-piece compound preparation with a complete treatment plan in the field of HIV treatment in mainland China.
Dote abalamib tablets (Simeike) are based on integrase inhibitors. In clinical trials, DTG had a low discontinuation rate due to adverse drug reactions (ADR) or virological failure, which were 5.8% and 0.5% respectively. In the SINGLE trial, the 48-week primary analysis showed that the proportion of patients who achieved virological suppression was better in the dolutegravir XxXABC/3TC group than in the FTC/TDF/ETC group. It can be seen that doptabalamid tablets (Suimeike) have obvious viral suppression effect and low incidence of side effects, making it a good choice for HIV patients.
How many days do I need to take Abalami Tablets?
The specific duration of taking Domitabalamid Tablets (Suimeike) is determined by the patient's own constitution and disease stage. The dosage of Dolutea Abalamid Tablets (Sumeikan) for the treatment of adult and adolescent patients is the same. The recommended dosage of Dolutegra Abalamid Tablets (Sumeike) is one tablet each time, once a day. Regardless of whether they are adults or adolescent patients, if their weight is less than 40kg, they should not take Trimax, because Trimax is a fixed-dose tablet and the dose cannot be reduced, and patients cannot take the medicine at will. Individual formulations of dolutegravir, abacavir, or lamivudine may be used if discontinuation or dose adjustment of one of the active ingredients is necessary and, in these circumstances, physicians should refer to the respective product information for these medicines.
The above is the introduction about (Sui Mei Kai), I hope it can help everyone. If patients have other questions about the drug (such as drug price, purchasing channels, etc.), they can consult the medical companion travel service.
Recommended related hot articles: /newsDetail/85356.html
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)